中国创新药企破纪录!三生制药与辉瑞百亿BD引爆全球双抗赛道

新浪证券
27 May

近日,中国创新药企三生制药宣布与跨国药企辉瑞达成一项创纪录的License out(对外授权)协议,总金额最高可达60.5亿美元(约合人民币435亿元)。这一交易不仅刷新了中国药企单品种出海交易的金额纪录,更标志着中国创新药企在全球双特异性抗体赛道的强势崛起。交易细节:首付款+里程碑付款+梯度分成根据协议,辉瑞将获得三生制药自主研发的PD-1/VEGF双特异性抗体SSGJ-707在除中国大陆以外...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10